Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.18 – $0.37
3% from low
Exchange
OTC Link
CS
Borrow rate
5.58%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $412.0K | $2.4M | $1.3M | $1.0M | $1.7M | $1.9M | $1.4M | $1.4M |
| Cost of revenue | $18.2M | $14.1M | $33.6M | $20.3M | $1.5M | $27.7M | $2.0M | $2.3M |
| Gross profit | −$17.7M | −$11.7M | −$32.3M | −$19.3M | $135.0K | −$25.8M | $1.4M | −$959.0K |
| Gross margin | -4306.3% | -485.3% | -2505.5% | -1920.7% | 8.0% | -1335.3% | 100.0% | -69.6% |
| R&D | $18.2M | $14.1M | $33.6M | $20.3M | $35.5M | $27.7M | $34.9M | $28.8M |
| Operating income | −$41.5M | −$27.5M | −$86.6M | −$52.7M | −$67.2M | −$55.5M | −$66.5M | −$59.9M |
| EBITDA | −$24.6M | −$17.8M | −$520.9M | $184.7M | −$97.4M | −$55.3M | −$73.6M | −$57.6M |
| Net income | −$35.8M | −$20.8M | −$529.8M | $179.1M | −$105.0M | −$62.6M | −$83.8M | −$61.5M |
| Net margin | -8687.9% | -863.6% | -41039.6% | 17823.5% | -6240.8% | -3240.1% | -6062.1% | -4461.3% |
| EPS (diluted) | -0.12 | -0.04 | -0.73 | -0.06 | -0.10 | -0.06 | -0.07 | -0.04 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.05 | $-0.05–$-0.05 | 1 |
| 2027 | $39M | $-0.07 | $-0.07–$-0.07 | 1 |
Forward consensus · source: Financial Modeling Prep
NORTHWEST BIOTHRPUTCS INC
No one on the platform currently holds NWBO.
No tracked institution reports a position in NWBO as of their last filing.
| Execution date | Ratio |
|---|---|
| 2012-09-26 | 1-for-16reverse |
No one on the platform has traded NWBO yet.
| $342M |
| — |
| FGHQFFrontage Holdings Corporation | $0.14 | +0.00% | $274M | — |
| HLOSFHealios K.K. | $1.80 | +0.00% | $194M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 152.5× sales vs its 383.3× historical median P/S.
Fair value ≈ $0.46 · price $0.18 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$NWBO Irony would be our company going to the UK to seek independence from the OTC.
View on StockTwits ↗$NWBO Its tuesday and approval will come Soon this shitshow is over. Lfg🦬💎🦍
View on StockTwits ↗$NWBO I am a bit tired of waiting for anything to happen therefore I decided it’s time to go fishing ! Lofoten Islands Norway Baby ! See ya! 👋 Îll be back in September…
View on StockTwits ↗$NWBO using this logic there is a monthly approval. Always happens close or approval. We are nowhere near approval! Absolutely nonsense statement One of the biggest clowns on X
View on StockTwits ↗$NWBO if Mgmt gives some Donations thru Lobbiest Lord or middle man in U.K .... .. things can be dramatically change .....
View on StockTwits ↗$NWBO Has anyone ever considered this; We know WS is corrupt, otc is corrupt. they tried to destroy this company through spoofing and massive shorting. widdled down it's market cap hoping it could make it worthless and run out of money to bury it. Now besides corporate greed and corruption does anyone think this is just one sided? You develop the means to cure cancer; and the rest of the medical industry is only there to profit through conventional uneffective means that have been in place for decades. Very powerful industry. a classic case of David vs Gollieth. They not only tried but they lost against NWBO. Now the little engine that could, is going to tow the line..This is what makes this company above all others precident setting.
View on StockTwits ↗$NWBO I wonder how much longer this stock is gonna make me look like an idiot to my wife, family, and friends.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.